Clinical trials: Mycophenolate Mofetil
Disorder Related to Lung Transplantation, Bronchiolitis Obliterans
Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients
This is a single-center pilot study to investigate the efficacy and safety of aerosolized liposomal cyclosporine A in the treatment of chronic rejection in lung transplant recipients with bronchiolitis obliterans syndrome (BOS).
- Conditions
- Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
- Trial name
- NCT01650545
- Testing
- Liposomal aerosol cyclosporine, standard immune suppression, oral
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Maryland, Baltimore
Liver Transplant Rejection, Immunosuppression
Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents
This study is being done with the purpose of trying to understand if and why transplant recipients may develop tolerance to their transplanted organ.
- Trial name
- NCT01678937
- Testing
- Blood Draw - Rapamycin, Blood Draw from Control Subjects, Blood Draw - CyA
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Bullous Pemphigoid
Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid
To investigate the safety and efficacy of oral methylprednisolone combined with azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
- Trial name
- NCT00431119
- Testing
- Azathioprine or Mycophenolate mofetil
- Where
- 11 sites in Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Muenster
Aplastic Anaemia
A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
Aplastic anemia (AA) is a bone marrow failure disorder characterized by pancytopenia and hypoplastic bone marrow caused by the decrease of hematopoietic stem cells.
- Trial name
- NCT07499284
- Testing
- Haploidentical hematopoietic cell transplantation combined with unrelated cord blood stem cells, Haploidentical hematopoietic cell transplantation
- Where
- 4 sites in China
- Volunteers
- 224 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in…
- Trial name
- NCT02028884
- Testing
- Satralizumab, Baseline Treatment
- Where
- 40 sites in United States, France and 9 more
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
Absence; Kidney
Sirolimus Conversions in African-American Renal Transplant Recipients
This study's focus is to compare the level effectiveness and safety of regimens involving Sirolimus, Cellcept and steroid to Prograf, Sirolimus and steroid in African-American recipients of kidney transplants.
- Trial name
- NCT01005706
- Testing
- rapamune, mycophenolate mofetil and steroid, tacrolimus, sirolimus and steroid
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical University of South Carolina
Lung and Heart-lung Transplantation
Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation
The purpose of this study is to evaluate in lung or heart-lung transplant patients on tacrolimus and mycophenolate the impact of optimized mofetil (MMF) therapeutic drug monitoring and dose adjustment of both drugs on the…
- Trial name
- BASALT (NCT00975663)
- Testing
- Tacrolimus and MMF
- Where
- 9 sites in Belgium, France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Limoges
Renal Transplantation
Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant
To compare the change in renal function between CsA or MMF withdrawal from before to 12 months after drug withdrawal in renal transplant recipients on triple immunosuppressive therapy
- Trial name
- NCT00148252
- Testing
- Mycophenolate mofetil withdrawal, Cyclosporione A withdrawal
- Where
- 9 sites in Norway
- Volunteers
- 298 people
- Sponsor
- University of Oslo School of Pharmacy
FED
Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting Conditions
To compare the bioavailability and characterise the pharmacokinetic profile of the sponsor's test formulation with respect to the reference formulation Cellcept® 500 mg tablets, in healthy, adult, human male subjects under…
- Trial name
- NCT01283867
- Testing
- Mycophenolate Mofetil
- Where
- India
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Neurological Disorder, Autoimmune Diseases
Disease-Modifying Treatments for Myasthenia Gravis
This study is designed to address the evidence gaps in a real-world setting and help patients with MG choose treatments that are best suited to them.
- Trial name
- PROMISE-MG (NCT03490539)
- Testing
- Mycophenolate Mofetil, Azathioprine
- Where
- 19 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- Duke University
Primary Renal Allograft Candidate, Kidney Transplantation
Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen
The primary objective is to evaluate a NULOJIX® (belatacept) based regimens as a means of improving long-term graft function without increasing the risks of immunologic graft injury by avoiding both calcineurin inhibitors (CNIs)…
- Trial name
- NCT01856257
- Testing
- Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant
The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.
The study is being done to compare the safety and effects (good and bad) of three different combinations of immunosuppression drugs used by kidney transplant recipients while also looking at their kidney function.
- Trial name
- NCT00275522
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just completed an 8 month trial of MMF treatment alone.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446251
- Testing
- Rituximab, Mycophenolate mofetil (MMF)
- Volunteers
- 14 people
- Sponsor
- University of Washington
End-Stage Renal Disease
Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients
Patient failure to take medications as prescribed (medication non-adherence) is now identified as an important cause of kidney transplant failure.
- Trial name
- OnceDaily (NCT02426502)
- Testing
- Conversion to Advagraf, conversion of non-immunosuppressant drugs to once daily, Conversion to once daily MPA
- Where
- 3 sites in Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Fanconi Anemia
Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia
RATIONALE: Giving chemotherapy, such as cyclophosphamide and fludarabine, before a donor stem cell transplant helps to remove the patient's cells to allow for the transplant cells to take and grow.
- Trial name
- NCT00630253
- Testing
- Anti-Thymocyte Globulin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Refractory Plasma Cell Myeloma
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
This phase II trial studies the side-effects and anti-cancer effects of giving an autologous or syngeneic stem cell transplant followed by an allogeneic donor stem cell transplant and bortezomib.
- Trial name
- NCT00793572
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Cyclosporine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fred Hutchinson Cancer Center
Renal Transplantation
Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients
Cyclosporine (CNI), a potent immunosuppressive drug used in transplant recipients to prevent graft rejection, can cause renal impairment in some patients.
- Trial name
- NCT00443937
- Testing
- enteric-coated mycophenolate sodium, everolimus
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Charite University, Berlin, Germany
Sickle Cell Disease
HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
Sickle cell disease (SCD) is the most common inherited blood disorder in Saudi Arabia . Its clinical severity is widely heterogeneous among patients who share the same genetic mutation .
- Trial name
- NCT02776202
- Testing
- Fludarabine monophosphate
- Where
- Saudi Arabia
- Volunteers
- 15 people
- Sponsor
- National Guard Health Affairs
Kidney Transplantation
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.
- Trial name
- NCT06365437
- Testing
- TCD601, Tacrolimus (TAC), Corticosteroids (CS)
- Where
- 7 sites in Austria, Spain and 1 more
- Volunteers
- 33 people
- Sponsor
- ITB-Med LLC
Leukemia, Chronic Myeloid, Myelodysplastic Syndromes
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Purpose There is a growing evidence of high efficacy of post-transplantation cyclophocphomide (PTCy)-based GVHD prophylaxis in haploidentical and matched related and unrelated bone marrow transplantation.
- Conditions
- Leukemia, Chronic Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Trial name
- NCT02627573
- Testing
- Unrelated allogeneic stem cell transplantation, Busulfan, Fludarabine monophosphate
- Where
- Russia
- Volunteers
- 32 people
- Sponsor
- St. Petersburg State Pavlov Medical University